Age-specific differences in breast cancer treatment between screen-detected and non-screen-detected breast cancers in women aged 40–74 years at diagnosis in Sweden 2008–2017
DOI:
https://doi.org/10.2340/1651-226X.2024.40200Keywords:
Breast cancer, screening programme, mammography, surgery, chemotherapy, radiotherapy, endocrine therapy, antibody therapyAbstract
Background and purpose: We have recently demonstrated that screen-detected invasive breast cancers had more favourable tumour characteristics than non-screen-detected. The objective of the study was to analyse differences in breast cancer treatment between screen-detected and non-screen-detected cases by age at diagnosis, with and without adjustment for tumour (T) and nodal (N) status, within a nationwide, population-based mammography screening programme utilising register data.
Material and methods: Data spanning 2008–2017 were collected from the National Quality Register for Breast Cancer. Multivariable logistic regression analysis was used to estimate odds ratios and 95% confidence intervals for treatment disparities between screen-detected and non-screen-detected breast cancer.
Results: Among 46,481 women diagnosed with invasive breast cancer aged 40–74 and invited for mammography screening, significant differences in treatment were observed. Screen-detected cases showed higher likelihoods of partial mastectomy compared to mastectomy, endocrine therapy, and radiotherapy, whereas chemotherapy and antibody therapy were less likely compared to non-screen-detected cases. However, when adjusting for surgery type, screen-detected cases showed lower likelihoods of radiotherapy. Age at diagnosis significantly influenced treatment odds ratios, with interactions observed for all treatments except radiotherapy adjusted for surgery. Differences increased with age, except for endocrine therapy. Radiotherapy adjusted for surgery type showed no age-related interaction. Adjusting for T and N did not alter these patterns.
Interpretation: In general, screen-detected cases received less aggressive treatment, such as mastectomy, chemotherapy, and antibody therapy, compared to non-screen-detected cases. Disparities increased with age, except for endocrine therapy and radiotherapy adjusted for surgery. Differences persisted after adjusting for T and N, suggesting that these factors cannot solely explain the results.
Downloads
References
Statistics on new detected cancer cases 2021 (The National Board of Health and Welfare, in Swedish). 2022. [Cited date June 27, 2024] Available from: https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/statistik/2022-12-8308.pdf
Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778–1786. https://doi.org/10.1016/S0140-6736(12)61611-0 DOI: https://doi.org/10.1016/S0140-6736(12)61611-0
Nyström L, Rutqvist L, Wall S, Lindgren A, Lindqvist M, Rydén S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet. 1993;341:973–978. https://doi.org/10.1016/0140-6736(93)91067-V DOI: https://doi.org/10.1016/0140-6736(93)91067-V
European guidelines on breast cancer screening and diagnosis (European Commission). 2023. [Cited date June 27, 2024] Available from: https://healthcare-quality.jrc.ec.europa.eu/ecibc/european-breast-cancer-guidelines
Fancellu A, Sanna V, Sedda ML, Delrio D, Cottu P, Spanu A, et al. Benefits of organized mammographic screening programs in women aged 50 to 69 years: A surgical perspective. Clin Breast Cancer. 2019;19:e637–e642. https://doi.org/10.1016/j.clbc.2019.04.013 DOI: https://doi.org/10.1016/j.clbc.2019.04.013
Kobayashi N, Hikichi M, Ushimado K, Sugioka A, Kiriyama Y, Kuroda M, et al. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival. Clin Transl Oncol. 2017;19:1232–1240. https://doi.org/10.1007/s12094-017-1660-z DOI: https://doi.org/10.1007/s12094-017-1660-z
Olsson A, Borgquist S, Butt S, Zackrisson S, Landberg G, Manjer J. Tumour-related factors and prognosis in breast cancer detected by screening. Br J Surg Soc. 2012;99:78–87. https://doi.org/10.1002/bjs.7757 DOI: https://doi.org/10.1002/bjs.7757
Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, et al. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer. 2009;101:1338–1344. https://doi.org/10.1038/sj.bjc.6605317 DOI: https://doi.org/10.1038/sj.bjc.6605317
Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA. 2004;292:1064–1073. https://doi.org/10.1001/jama.292.9.1064 DOI: https://doi.org/10.1001/jama.292.9.1064
Sihto H, Lundin J, Lehtimaki T, Sarlomo-Rikala M, Butzow R, Holli K, et al. Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res. 2008;14:4103–4110. https://doi.org/10.1158/1078-0432.CCR-07-5003 DOI: https://doi.org/10.1158/1078-0432.CCR-07-5003
Jonsson H, Andersson A, Mao Z, Nystrom L. Age-specific differences in tumour characteristics between screen-detected and non-screen-detected breast cancers in women aged 40–74 at diagnosis in Sweden from 2008 to 2017. J Med Screening. 2024 March 7 [Available online]. https://doi.org/10.1177/09691413241237616 DOI: https://doi.org/10.1177/09691413241237616
National quality register for breast cancer (Regional Cancer Centers in collaboration, in Swedish). 2023. [Cited date June 27, 2024] Available from: https://cancercentrum.se/samverkan/cancerdiagnoser/brost/kvalitetsregister/
Interactive report: National quality register for breast cancer (In Swedish). 2023. [Cited date June 27, 2024] Available from: https://statistik.incanet.se/brostcancer/
Broman C, Edbom T. National evaluation – breast cancer screening with mammography (In Swedish). The National Board of Health and Welfare, Stockholm; 2022.
R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022. [Cited date June 27, 2024] Available from: https://www.R-project.org/
Validation of National quality register for breast cancer (Regional Cancer Centers in collaboration, in Swedish). 2015. [Cited date June 27, 2024] Available from: https://cancercentrum.se/globalassets/cancerdiagnoser/brost/kvalitetsregister/rapport_master_validering_brostregister2015-10-14.pdf
Wennman-Larsen A, Nilsson MI, Saboonchi F, Olsson M, Alexanderson K, Fornander T, et al. Can breast cancer register data on recommended adjuvant treatment be used as a proxy for actually given treatment? Eur J Oncol Nurs. 2016;22:1–7. https://doi.org/10.1016/j.ejon.2016.02.010 DOI: https://doi.org/10.1016/j.ejon.2016.02.010
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Håkan Jonsson, Anne Andersson, Zheng Mao, Lennarth Nyström
This work is licensed under a Creative Commons Attribution 4.0 International License.
